ConductScience.org, home
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
API referenceFor AI assistants

Trial · NCT03409744

Results by group62

Each measurement the trial posted, group by group, in the words and numbers it posted.

21 to 40 of 62

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 8-78.0Standard Deviation 59.78mg/dL
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 24-70.5Standard Deviation 61.96mg/dL
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 48-69.4Standard Deviation 69.95mg/dL
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 72-73.9Standard Deviation 61.51mg/dL
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 96-71.5Standard Deviation 66.66mg/dL
Absolute Change in Apo B Over TimeOverall Study Total EvinacumabWeek 120-70.7Standard Deviation 76.05mg/dL
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 8-48.47Standard Deviation 28.369Percentage of change
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 24-46.14Standard Deviation 29.117Percentage of change
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 48-45.15Standard Deviation 33.566Percentage of change
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 72-46.69Standard Deviation 28.534Percentage of change
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 96-40.88Standard Deviation 46.588Percentage of change
Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over TimeOverall Study Total EvinacumabWeek 120-35.85Standard Deviation 58.374Percentage of change
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 8-153.7Standard Deviation 115.66mg/dL
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 24-143.9Standard Deviation 125.03mg/dL
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 48-144.1Standard Deviation 136.95mg/dL
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 72-147.3Standard Deviation 122.76mg/dL
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 96-144.5Standard Deviation 131.15mg/dL
Absolute Change in Non-HDL-C Over TimeOverall Study Total EvinacumabWeek 120-142.9Standard Deviation 136.65mg/dL
Percent Change in Total Cholesterol (TC) Over TimeOverall Study Total EvinacumabWeek 8-47.04Standard Deviation 20.722Percentage of change
Percent Change in Total Cholesterol (TC) Over TimeOverall Study Total EvinacumabWeek 24-44.17Standard Deviation 24.224Percentage of change

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03409744/results?page=2

API referenceFor AI assistants